NCT07267273 Betamethasone Phonophoresis For Vitiligo
| NCT ID | NCT07267273 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Cairo University |
| Condition | Vitiligo |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2025-11-10 |
| Primary Completion | 2026-02-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2025-11-10 with a primary completion date of 2026-02-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Vitiligo is a skin disorder that results in the formation of depigmented patches or hypopigmented macules due to selective destruction or reduction of melanocytes the cells that produce pigment in our skin. Vitiligo affects 0.1-2% of the World's population. People of all skin types and all ages can be affecte. In most of the cases, white patches develop or expand slowly overtime, and in some cases it never progress and remains stable . Vitiligo can be segmental or non-segmental depending upon the morphology of the clinical involvement. It can also be classified as stable or unstable based on the activity of disease. Steroids act as anti-inflammatory and immunosuppressant agents. Even if different classes of steroids are now available, the mid- potent ones (e.g. betamethasone dipropionate 0.05% cream, 0.05% clobetasol propionate ointment) are usually preferred for the treatment of young patients . Now days, topical corticosteroids are the most commonly prescribed agents in treatment of dermatologic conditions .Almost all treatments of vitiligo have borrowed from therapies whose prime targets have been another disease.
Eligibility Criteria
Inclusion Criteria: * Male and female patients diagnosed with vitiligo. * Medically and psychologically stable patients. * Good cognitive abilities to understand the requirements of the study. * All patients enrolled to the study will have their informed consent. * they had no contraindications to the use of therapeutic ultrasound Exclusion Criteria: * Pregnancy or lactation. * Immunosuppression. * Alcohol abuse. * History of spontaneous re-pigmentation of lesions. * Presence of skin characteristics that may interfere with study assessment. * Active bacterial/viral infection. * Patients on other immune suppressants and phototherapy * Patients currently participating in any other clinical study * Uncooperative patients.
Contact & Investigator
Nisreen Afify Abd-Elrasheed, Professor
STUDY CHAIR
Physical Therapy for Surgery,Faculty of Physical Therapy,Cairo University
Frequently Asked Questions
Who can join the NCT07267273 clinical trial?
This trial is open to participants of all sexes, aged 25 Years or older, up to 40 Years, studying Vitiligo. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07267273 currently recruiting?
Yes, NCT07267273 is actively recruiting participants. Contact the research team at Olasabry17@yahoo.com for enrollment information.
Where is the NCT07267273 trial being conducted?
This trial is being conducted at Cairo, Egypt.
Who is sponsoring the NCT07267273 clinical trial?
NCT07267273 is sponsored by Cairo University. The principal investigator is Nisreen Afify Abd-Elrasheed, Professor at Physical Therapy for Surgery,Faculty of Physical Therapy,Cairo University. The trial plans to enroll 60 participants.